The effects of oregano oil on fungal infections associated with metabolic syndrome

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60162694%3AG45__%2F20%3A00555806" target="_blank" >RIV/60162694:G45__/20:00555806 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.revistadechimie.ro/pdf/51%20GHITEA%20T%201%2020.pdf" target="_blank" >https://www.revistadechimie.ro/pdf/51%20GHITEA%20T%201%2020.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.37358/RC.20.1.7854" target="_blank" >10.37358/RC.20.1.7854</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The effects of oregano oil on fungal infections associated with metabolic syndrome

Popis výsledku v původním jazyce

This study aims to compare the evolution of mycosis associated with metabolic syndrome under allopathic treatment compared to phytotherapy using oregano essential oil. The study was conducted over a period of 6 months, on a total of 72 patients diagnosed with fungal infections associated with metabolic syndrome. The patients were divided into 3 groups, depending on the administered treatment: group 1: 24 patients who received allopathic treatment; group 2: 24 patients who received oregano oil treatment; group 3: control, which did not undergo any antifungal treatment. All three groups were subjected to specific diet therapy for mycosis. The patients were initially evaluated at 10 days after the begining of the treatment (to track mycotic disease evolution in the acute phase), at 60 days (to evaluate the recurrence of mycoses) and at 180 days to track recurrent disease. Most infections were acute (77.78%), the chronic ones representing only 5.56% of cases. There were also 12 cases with recurrent infections (16.67%), out of which 6 cases (8.33%) had previously shown resistance to Nystatin. In the 72 cases there was a sensitivity of 100.00% for oregano oil and Ketaconazolum, insignificantly higher than for Myconazolum (97.22%, p=0.157), but significantly higher than for Clotrimazolum and Nystatinum (94.44%, p=0.0437), Variconazole and Fluconazole (88.89%, p=0.0038) and Itraconazole (86.11%, p=0.0011). The results of this study showed an increased efficiency of oregano oil on the symptomatic and paraclinical improvement of mycotic infections in the study, both on short term and on long term, which was completed with high tolerability.

Název v anglickém jazyce

The effects of oregano oil on fungal infections associated with metabolic syndrome

Popis výsledku anglicky

This study aims to compare the evolution of mycosis associated with metabolic syndrome under allopathic treatment compared to phytotherapy using oregano essential oil. The study was conducted over a period of 6 months, on a total of 72 patients diagnosed with fungal infections associated with metabolic syndrome. The patients were divided into 3 groups, depending on the administered treatment: group 1: 24 patients who received allopathic treatment; group 2: 24 patients who received oregano oil treatment; group 3: control, which did not undergo any antifungal treatment. All three groups were subjected to specific diet therapy for mycosis. The patients were initially evaluated at 10 days after the begining of the treatment (to track mycotic disease evolution in the acute phase), at 60 days (to evaluate the recurrence of mycoses) and at 180 days to track recurrent disease. Most infections were acute (77.78%), the chronic ones representing only 5.56% of cases. There were also 12 cases with recurrent infections (16.67%), out of which 6 cases (8.33%) had previously shown resistance to Nystatin. In the 72 cases there was a sensitivity of 100.00% for oregano oil and Ketaconazolum, insignificantly higher than for Myconazolum (97.22%, p=0.157), but significantly higher than for Clotrimazolum and Nystatinum (94.44%, p=0.0437), Variconazole and Fluconazole (88.89%, p=0.0038) and Itraconazole (86.11%, p=0.0011). The results of this study showed an increased efficiency of oregano oil on the symptomatic and paraclinical improvement of mycotic infections in the study, both on short term and on long term, which was completed with high tolerability.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

50902 - Social sciences, interdisciplinary

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Revista de Chimie

ISSN

0034-7752

e-ISSN

—

Svazek periodika

71

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

RO - Rumunsko

Počet stran výsledku

7

Strana od-do

335-341

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85079246491